Navigation Links
AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Date:6/3/2013

NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL).  Results from the study were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).

This Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in patients with relapsed/refractory CLL and NHL. Secondary objectives included preliminary efficacy, including objective response rate (ORR), duration of response, time to progression, progression-free survival (PFS) and overall survival (OS). 

"The ABT-199 data underscore AbbVie's commitment to the development of treatments for some of the hardest-to-treat cancers like CLL and NHL," said Gary Gordon , M.D., divisional vice president, oncology clinical development, AbbVie. "Early trials of ABT-199 have shown the compound's potential in these hematological malignancies, which support the continuation of its clinical development program."

CLL Arm
As of April 2013, 56 patients have enrolled in the CLL arm of the Phase I trial, and 40 patients are currently active. Study participants were given a single oral dose of ABT-199, followed by six days without medication, before continuous once-daily dosing. Due to concerns over tumor lysis syndrome (TLS), the initial dose was reduced and daily dosing was modified. Single-agent activity was observed in the trial and warrants
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. StockCall Scrutinizes Pfizer, Merck & Co., Johnson & Johnson, and AbbVie
2. AbbVie to Present at Cowen and Company 33rd Annual Health Care Conference
3. AbbVie Declares Dividend and Announces Share Repurchase Program
4. JULABO USA Inc. Presents the New PRESTO® W91 and W92 Series of Highly Dynamic Temperature Control Systems
5. Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers
6. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
7. Trigemina Presents at American Pain Society 32nd Annual Scientific Meeting
8. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
9. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
10. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
11. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... San Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... three major conferences to develop new business relationships with local sponsors in southern California. ... services to facilitate their drug development processes and regulatory pathways., , ...
(Date:8/25/2015)... Aug. 25, 2015 Human Longevity, Inc. (HLI), the ... has joined the company as Chief Operating Officer. Winham, ... operations and technical experience, will report directly to HLI,s CEO, ... this new role as COO, Winham will be responsible for ... well as all facility operations. HLI currently has three locations ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2
... VIRGINIA BEACH, Va., Oct. 7, 2008 AMERIGROUP,Corporation ... will report its earnings,for the third quarter ended ... October 22, 2008. At 8:30 a.m. Eastern Time ... a conference call and webcast,to discuss earnings and ...
... of Lives, GERMANTOWN, Md., Oct. 7 ... development of medical,countermeasures for biodefense and emerging infectious ... for advanced development of a,vaccine to protect against ... Allergy and Infectious Diseases (NIAID), part of the ...
... Maryland, October 7 Orthocrat Ltd., announced,today ... purchased,TraumaCad(TM), a web-based pre-operative planning and digital ... used X-ray films and acetate,overlays to determine ... for,joint-replacement surgery. With the adoption of digital ...
Cached Biology Technology:AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 2Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses 3George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 2George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 3
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... of the greatest mysteries of modern coral reefs is how ... has long existed in the record of coral evolution. ... in sea level and changes in the Earth,s climate between ... many "old" corals went extinct, and the modern reef corals ...
... the University of Alberta have made a discovery that may ... cow disease, adapt in order to spread between various types ... discovered that a miniscule change in the prions, makeup appears ... mimic and recreate new strains with which it comes into ...
... For hundreds of years, naturalists and scientists have ... differences. But now, new genetic techniques are revealing ... visible differences. In a just-published study, evolutionary ... the American Museum of Natural History (AMNH) combine ...
Cached Biology News:University of Miami geologists to address the mystery of an evolution gap in reef corals 2Discovery may explain how prion diseases spread between different types of animals 2Researchers develop tools for discovering new species 2Researchers develop tools for discovering new species 3
...
... pAcGHLT-A,B,C Baculovirus ... Set,pAcGHLT-XylE Baculovirus ... Powder,Thrombin Dilution ... Cocktail,Insect Cell ...
...
... Plus accurately and conveniently controls the temperature at ... different temperature levels up to 99 C*, with ... as low as 5 C. The thermoblocks for ... tubes, and microplates enable a high degree of ...
Biology Products: